no, I'm sure it didn't suck as an investment. Congrats on the big gain. You must be one of the people that didn't get spooked by the pre-approval nose dive.
Anyway, my point was that, in my opinion, it kind of sucks as an acquisition target. If I was a big pharma, I would stay away from DNDN because I think it would be one big headache. Their therapy is very expensive (hard to get insurance companies to pay) and it has to be customized, not only for individual people (cells come out, cells go in) but for each cancer (specific antigens).
ZIOP on the other hand has 3 promising drugs that could each be used in multiple cancers with no customization and that are VERY cheap to manufacture and administer.
If you ask me, there is no comparison. I would be happy to acquire ziop but dndn, while an attractive technology/concept, just isn't practical as a money making venture.